ARVN Logo

Arvinas, Inc. (ARVN) 

NASDAQ$8.43
Market Cap
$579.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
461 of 924
Rank in Industry
271 of 527

ARVN Insider Trading Activity

ARVN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$771,6025100

Related Transactions

Loomis David KChief Accounting Officer0$02$26,731$-26,731
Cacace Angela MChief Scientific Officer0$01$70,238$-70,238
Taylor IanPresident, R&D0$01$150,752$-150,752
Houston John GPresident and CEO0$01$523,881$-523,881

About Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of â€¦

Insider Activity of Arvinas, Inc.

Over the last 12 months, insiders at Arvinas, Inc. have bought $0 and sold $771,602 worth of Arvinas, Inc. stock.

On average, over the past 5 years, insiders at Arvinas, Inc. have bought $21.11M and sold $29.52M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 285,714 shares for transaction amount of $20M was made by Ratcliffe Liam (director) on 2020‑12‑18.

List of Insider Buy and Sell Transactions, Arvinas, Inc.

2025-02-24SaleHouston John GPresident and CEO
31,338
0.0429%
$16.72$523,881+3.45%
2025-02-24SaleTaylor IanPresident, R&D
9,020
0.0123%
$16.71$150,752+3.45%
2025-02-24SaleCacace Angela MChief Scientific Officer
4,207
0.0057%
$16.70$70,238+3.45%
2025-02-24SaleLoomis David KChief Accounting Officer
1,214
0.0017%
$16.75$20,335+3.45%
2024-11-07SaleLoomis David KChief Accounting Officer
231
0.0003%
$27.69$6,396-32.70%
2024-02-23SaleHouston John GPresident and CEO
5,196
0.0095%
$47.05$244,472-44.89%
2024-02-23SaleCassidy Sean AChief Financial Officer
1,702
0.0031%
$47.05$80,079-44.89%
2024-02-23SaleTaylor IanChief Scientific Officer
1,701
0.0031%
$47.05$80,032-44.89%
2024-02-23SalePeck RonaldChief Medical Officer
1,699
0.0031%
$47.05$79,938-44.89%
2023-11-08SaleLoomis David KChief Accounting Officer
229
0.0004%
$17.05$3,904+80.56%
2023-08-11SalePeck RonaldChief Medical Officer
1,324
0.0024%
$24.39$32,289+20.32%
2023-03-01SaleHouston John GPresident and CEO
5,878
0.0107%
$29.53$173,577-14.30%
2023-03-01SaleCassidy Sean AChief Financial Officer
1,745
0.0032%
$29.53$51,530-14.30%
2023-03-01SaleTaylor IanChief Scientific Officer
1,051
0.0019%
$29.53$31,036-14.30%
2022-08-12SalePeck RonaldChief Medical Officer
1,258
0.0024%
$54.84$68,994-40.82%
2022-04-14SaleMorrison Briggs
10,754
0.0202%
$67.03$720,888-36.79%
2022-03-11SaleCassidy Sean AChief Financial Officer
15,000
0.029%
$70.00$1.05M-36.08%
2022-03-04SaleHouston John GPresident and CEO
6,024
0.0113%
$63.94$385,175-31.76%
2022-03-04SaleCassidy Sean AChief Financial Officer
1,593
0.003%
$63.94$101,856-31.76%
2022-03-04SaleTaylor IanChief Scientific Officer
869
0.0016%
$63.94$55,564-31.76%
Total: 99
*Gray background shows transactions not older than one year

Insider Historical Profitability

31.29%
Houston John GPresident and CEO
1157480
1.6831%
$9.76M111+24.92%
Taylor IanPresident, R&D
159121
0.2314%
$1.34M113+66.46%
RA CAPITAL MANAGEMENT, LLC
3138412
4.5635%
$26.46M10+24.92%
SHANNON TIMOTHY Mdirector
1653128
2.4038%
$13.94M511+45.5%
Flynn James E10 percent owner
411245
0.598%
$3.47M10+24.92%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$3,596,906
112
13.42%
$635.29M
$36,510,315
95
8.95%
$609.56M
$587,109,125
90
3.17%
$527.16M
$678,065,999
37
-13.32%
$603.22M
$94,912,877
34
-7.15%
$626.42M

ARVN Institutional Investors: Active Positions

Increased Positions109+50.23%12M+16.16%
Decreased Positions89-41.01%10M-13.61%
New Positions28New4MNew
Sold Out Positions36Sold Out6MSold Out
Total Postitions237+9.22%74M+2.55%

ARVN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$125,007.0010.24%7.06M+56,561+0.81%2024-12-31
Ecor1 Capital, Llc$119,059.009.75%6.73M00%2024-12-31
Blackrock, Inc.$116,221.009.52%6.57M+70,059+1.08%2024-12-31
Price T Rowe Associates Inc /Md/$72,623.005.95%4.1M+249,295+6.47%2024-12-31
Rtw Investments, Lp$59,017.004.83%3.33M+551,979+19.84%2024-12-31
Citadel Advisors Llc$54,386.004.45%3.07M+365,117+13.48%2024-12-31
Bellevue Group Ag$42,296.003.46%2.39M+3,000+0.13%2024-12-31
T. Rowe Price Investment Management, Inc.$39,086.003.2%2.21M+2MNew2024-12-31
Ubs Group Ag$36,081.002.95%2.04M+2M+332.26%2024-12-31
Jpmorgan Chase & Co$32,870.002.69%1.86M-472,225-20.27%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.